Summit Partners Public Asset Management, LLC Ascendis Pharma A/S Transaction History
Summit Partners Public Asset Management, LLC
- $3.3 Billion
- Q1 2025
A detailed history of Summit Partners Public Asset Management, LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Summit Partners Public Asset Management, LLC holds 24,300 shares of ASND stock, worth $4.32 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
24,300
Previous 24,600
1.22%
Holding current value
$4.32 Million
Previous $3.39 Million
11.84%
% of portfolio
0.11%
Previous 0.08%
Shares
7 transactions
Others Institutions Holding ASND
# of Institutions
270Shares Held
61.9MCall Options Held
151KPut Options Held
226K-
Ra Capital Management, L.P. Boston, MA10.3MShares$1.83 Billion33.28% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$974 Million4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.22MShares$927 Million13.16% of portfolio
-
Janus Henderson Group PLC London, X04.49MShares$797 Million0.4% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$756 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $9.92B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...